Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation

Yuko Sugiura, Yoshihiko Soga, Kokoro Yamabe, Soichiro Tsutani, Ichiro Tanimoto, Hiroshi Maeda, Susumu Kokeguchi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The commercial saliva substitute Oralbalance® has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that Oralbalance® has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of Oralbalance® on oral mucosal total bacterial counts in patients undergoing HCT. Methods: A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of Oralbalance® use, bacterial samples were obtained from patients by wiping an area of ω1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined. Results: No significant increase in bacterial count was observed with use of Oralbalance®. None of the patients showed bacterial counts above the range found in healthy controls after using Oralbalance®. Conclusions: In neutropenic patients undergoing HCT, Oralbalance® did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using Oralbalance® may alleviate the symptoms induced by hyposalivation without promoting infection.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalSupportive Care in Cancer
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Bacterial Load
Cell Transplantation
Mouth Mucosa
Saliva
Xerostomia
16S Ribosomal RNA
Whole-Body Irradiation
Head and Neck Neoplasms
Infection
rRNA Genes
Healthy Volunteers
Bacteria
Drug Therapy
Polymerase Chain Reaction

Keywords

  • Hematopoietic cell transplantation
  • Saliva substitute
  • Xerostomia

ASJC Scopus subject areas

  • Oncology

Cite this

Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. / Sugiura, Yuko; Soga, Yoshihiko; Yamabe, Kokoro; Tsutani, Soichiro; Tanimoto, Ichiro; Maeda, Hiroshi; Kokeguchi, Susumu; Fujii, Nobuharu; Ishimaru, Fumihiko; Tanimoto, Mitsune; Nishimura, Fusanori; Takashiba, Shogo.

In: Supportive Care in Cancer, Vol. 18, No. 3, 03.2010, p. 395-398.

Research output: Contribution to journalArticle

Sugiura, Yuko ; Soga, Yoshihiko ; Yamabe, Kokoro ; Tsutani, Soichiro ; Tanimoto, Ichiro ; Maeda, Hiroshi ; Kokeguchi, Susumu ; Fujii, Nobuharu ; Ishimaru, Fumihiko ; Tanimoto, Mitsune ; Nishimura, Fusanori ; Takashiba, Shogo. / Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. In: Supportive Care in Cancer. 2010 ; Vol. 18, No. 3. pp. 395-398.
@article{26dd80278a8240b9bae32c4f2c362041,
title = "Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation",
abstract = "Purpose: The commercial saliva substitute Oralbalance{\circledR} has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. Oralbalance{\circledR} may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that Oralbalance{\circledR} has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of Oralbalance{\circledR} on oral mucosal total bacterial counts in patients undergoing HCT. Methods: A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of Oralbalance{\circledR} use, bacterial samples were obtained from patients by wiping an area of ω1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined. Results: No significant increase in bacterial count was observed with use of Oralbalance{\circledR}. None of the patients showed bacterial counts above the range found in healthy controls after using Oralbalance{\circledR}. Conclusions: In neutropenic patients undergoing HCT, Oralbalance{\circledR} did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using Oralbalance{\circledR} may alleviate the symptoms induced by hyposalivation without promoting infection.",
keywords = "Hematopoietic cell transplantation, Saliva substitute, Xerostomia",
author = "Yuko Sugiura and Yoshihiko Soga and Kokoro Yamabe and Soichiro Tsutani and Ichiro Tanimoto and Hiroshi Maeda and Susumu Kokeguchi and Nobuharu Fujii and Fumihiko Ishimaru and Mitsune Tanimoto and Fusanori Nishimura and Shogo Takashiba",
year = "2010",
month = "3",
doi = "10.1007/s00520-009-0789-x",
language = "English",
volume = "18",
pages = "395--398",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation

AU - Sugiura, Yuko

AU - Soga, Yoshihiko

AU - Yamabe, Kokoro

AU - Tsutani, Soichiro

AU - Tanimoto, Ichiro

AU - Maeda, Hiroshi

AU - Kokeguchi, Susumu

AU - Fujii, Nobuharu

AU - Ishimaru, Fumihiko

AU - Tanimoto, Mitsune

AU - Nishimura, Fusanori

AU - Takashiba, Shogo

PY - 2010/3

Y1 - 2010/3

N2 - Purpose: The commercial saliva substitute Oralbalance® has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that Oralbalance® has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of Oralbalance® on oral mucosal total bacterial counts in patients undergoing HCT. Methods: A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of Oralbalance® use, bacterial samples were obtained from patients by wiping an area of ω1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined. Results: No significant increase in bacterial count was observed with use of Oralbalance®. None of the patients showed bacterial counts above the range found in healthy controls after using Oralbalance®. Conclusions: In neutropenic patients undergoing HCT, Oralbalance® did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using Oralbalance® may alleviate the symptoms induced by hyposalivation without promoting infection.

AB - Purpose: The commercial saliva substitute Oralbalance® has been reported to alleviate symptoms of postradiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are in a severely compromised condition, and saliva substitute must not promote infection. We reported previously that Oralbalance® has antimicrobial effects against microbial species detected during HCT in vitro. This study was performed to determine the in vivo effects of Oralbalance® on oral mucosal total bacterial counts in patients undergoing HCT. Methods: A total of 18 neutropenic patients undergoing HCT were enrolled in this study. Before and after 1 week of Oralbalance® use, bacterial samples were obtained from patients by wiping an area of ω1 cm on the buccal mucosa with sterilized cotton swabs. Total bacterial counts of the obtained samples were examined by quantitative polymerase chain reaction amplification of the bacterial 16S ribosomal RNA gene. As controls, bacterial samples were also obtained from ten healthy subjects, and total bacterial counts were examined. Results: No significant increase in bacterial count was observed with use of Oralbalance®. None of the patients showed bacterial counts above the range found in healthy controls after using Oralbalance®. Conclusions: In neutropenic patients undergoing HCT, Oralbalance® did not increase the total counts of oral mucosal bacteria beyond the range found in healthy controls. Oral care using Oralbalance® may alleviate the symptoms induced by hyposalivation without promoting infection.

KW - Hematopoietic cell transplantation

KW - Saliva substitute

KW - Xerostomia

UR - http://www.scopus.com/inward/record.url?scp=77949265486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949265486&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0789-x

DO - 10.1007/s00520-009-0789-x

M3 - Article

VL - 18

SP - 395

EP - 398

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -